Aug 19 (Reuters) - Bioton S.A.:
* SAID ON FRIDAY THAT HARBIN GLORIA PHARMACEUTICALS HAS TERMINATED DEAL FOR SUPPLY AND DISTRIBUTION OF BIOTON’S INSULIN PRODUCTS ON CHINESE MARKET
* SAID THAT HARBIN GLORIA PHARMACEUTICALS HAS CITED CHANGES ON CHINESE PHARMACEUTICAL MARKET AS REASON FOR TERMINATION OF DEAL
* HARBIN GLORIA PHARMACEUTICALS ALSO SAID THAT IT WAS UNABLE TO MEET THE SALES FORECASTS AGREED IN DEAL
* SAID THAT FOR A LONG TIME THERE HAVE BEEN PROBLEMS WITH IMPLEMENTATION OF DEAL BY HARBIN GLORIA PHARMACEUTICALS
* SAID THIS SITUATION WAS REFLECTED IN FINANCIAL STATEMENTS OF COMPANY IN 2018 AND WILL AFFECT ITS RESULTS IN 2019
Source text for Eikon:
Further company coverage: (Gdynia Newsroom)
